ABCL NASDAQ
AbCellera Biologics Inc.
1W: +9.6%
1M: -7.8%
3M: +138.0%
YTD: +274.1%
1Y: +126.7%
3Y: +197.0%
5Y: -19.7%
$12.83
+0.75 (+6.21%)
Weekly Expected Move ±10.2%
$9
$11
$12
$13
$14
Credit Risk of going bust: higher than 55% of companies Debt: 3.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.07 (down 99.5%), AbCellera Biologics Inc. would be worth roughly what it owes.
Total debt $135.6M against a stock market value of $3.91B.
Distance to default 4.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $67.8M (short-term plus half of long-term), stock volatility 82.8%; Altman Z'' 4.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $135.6M against a stock market value of $3.91B.
Distance to default 4.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $67.8M (short-term plus half of long-term), stock volatility 82.8%; Altman Z'' 4.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
No Supply Chain Data
No business relationships found for ABCL in SEC 8-K filings.
This may mean the company hasn't filed material agreements or acquisitions in the covered period (2021–2026), or the company may not have a CIK-to-ticker mapping.